A detailed history of Addison Capital CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Addison Capital CO holds 8,323 shares of ABBV stock, worth $1.43 Million. This represents 0.77% of its overall portfolio holdings.

Number of Shares
8,323
Previous 8,035 3.58%
Holding current value
$1.43 Million
Previous $1.25 Million 21.69%
% of portfolio
0.77%
Previous 0.79%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$159.82 - $182.1 $46,028 - $52,444
288 Added 3.58%
8,323 $1.52 Million
Q4 2023

Feb 08, 2024

BUY
$137.6 - $154.97 $102,099 - $114,987
742 Added 10.17%
8,035 $1.25 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $21,107 - $24,434
-158 Reduced 2.12%
7,293 $1.09 Million
Q2 2023

Aug 18, 2023

SELL
$132.51 - $164.9 $29,417 - $36,607
-222 Reduced 2.89%
7,451 $1 Million
Q1 2023

Apr 13, 2023

SELL
$144.61 - $166.54 $3,759 - $4,330
-26 Reduced 0.34%
7,673 $1.22 Million
Q2 2022

Jul 11, 2022

SELL
$137.62 - $174.96 $62,066 - $78,906
-451 Reduced 5.53%
7,699 $1.18 Million
Q1 2022

Apr 11, 2022

BUY
$131.98 - $163.75 $143,858 - $178,487
1,090 Added 15.44%
8,150 $1.32 Million
Q4 2021

Jan 18, 2022

SELL
$107.43 - $135.93 $7,949 - $10,058
-74 Reduced 1.04%
7,060 $956,000
Q2 2021

Jul 16, 2021

BUY
$105.21 - $117.21 $100,896 - $112,404
959 Added 15.53%
7,134 $804,000
Q4 2020

Jan 12, 2021

SELL
$80.49 - $108.67 $965 - $1,304
-12 Reduced 0.19%
6,175 $662,000
Q3 2020

Oct 13, 2020

SELL
$85.91 - $100.83 $4,209 - $4,940
-49 Reduced 0.79%
6,187 $542,000
Q2 2020

Jul 16, 2020

BUY
$73.37 - $98.18 $457,535 - $612,250
6,236 New
6,236 $612,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $303B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Addison Capital CO Portfolio

Follow Addison Capital CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Addison Capital CO, based on Form 13F filings with the SEC.

News

Stay updated on Addison Capital CO with notifications on news.